7-OH: Effects, Risks, Withdrawal & Treatment

Samir Kadri
Dr. Jennie Stanford
Written by Samir Kadri on 17 November 2026
Medically reviewed by Dr. Jennie Stanford on 17 November 2026

Sold in gas stations, smoke shops, and online as tablets, gummies, and shots, 7-hydroxymitragynine (7-OH) is often marketed as a kratom product. However, commercially available 7-OH is often concentrated or semi-synthetically produced from a compound found in kratom in only trace amounts, yet it acts on the brain much like an opioid.

The FDA has warned about its addiction risk, and the DEA is preparing to temporarily place concentrated 7-OH products in Schedule I, a federal restriction that could take effect at any time.

Key takeaways:
  • 7-OH (7-hydroxymitragynine) is a potent kratom-derived compound that affects humans much like opioids. Concentrated or semi-synthetic 7-OH products act on the same brain receptors as morphine and oxycodone, causing pain relief and sedation in users.
  • 7-OH use carries serious risks, including dependence, addiction and overdose. Stopping after regular use can cause 7-OH withdrawal symptoms including anxiety, muscle aches, sweating, nausea and intense cravings.
  • 7-OH addiction is treatable. Medical detox, medication-assisted treatment such as buprenorphine, and ongoing therapy and support can help people safely stop using 7-OH and reduce the risk of relapse.
7-OH: Effects, Risks, Withdrawal & Treatment

7-OH explained

7-hydroxymitragynine, or 7-OH, is an alkaloid, a natural plant compound, found in the leaves of kratom (Mitragyna speciosa), a tropical tree native to Southeast Asia. In the raw leaf, it occurs only in trace amounts. Most of kratom’s effects come from a related alkaloid called mitragynine, which the body partly converts into 7-OH after it’s swallowed.

Today's 7-OH products differ significantly from the leaf. Most are semi-synthetic: manufacturers take mitragynine extracted from kratom and chemically convert it into the 7-OH that has been readily available on the US market. This produces far higher concentrations than any plant naturally contains. Because the amounts vary so much between products, it can be hard for anyone to know how strong a dose they’re taking.

How is 7-OH sold?

7-OH products are sold in several forms:

  • Tablets and pressed pills
  • Gummies and other edibles
  • Liquid shots
  • Powders and capsules
  • Dissolvable films and strips

These products are often packaged with kratom branding or labeled “natural,” which can make them seem as mild as kratom leaf. In reality, concentrated 7-OH is a much stronger substance with a higher risk of dependence.

How 7-OH works in the body

7-OH binds to the brain’s mu-opioid receptors, the same ones targeted by morphine and oxycodone. Much like other opioids, it can produce pain relief, feelings of calmness, and sedative effects, which contribute to its addiction risk. FDA analysis found it to be significantly more potent than morphine, and the agency notes it causes respiratory depression, dependence, and withdrawal symptoms associated with other opioids.

Because 7-OH works through opioid receptors, naloxone can restore normal breathing function if a person’s respiration has been impaired. In rat studies, naloxone fully reversed 7-OH-induced respiratory depression. While animal studies cannot be extrapolated directly to effects in humans, pharmacokinetics demonstrate that naloxone may wear off before the opioid effects have resolved. If respiratory depression returns, additional doses may be necessary. Always call emergency services after giving naloxone, and patients should be monitored for several hours after administration.

7-OH vs kratom: key differences

We’ve established that while 7-OH comes from kratom, it has fundamentally different effects when taken in its concentrated form. Below is a table that details the key differences between the two.

CategoryKratom (leaf)7-OH (concentrated)
What it isDried or crushed leaves of the kratom plant (mitragyna speciosa) containing many alkaloidsA single alkaloid found in the kratom plant, now made synthetically
7-OH contentTrace amounts only (under 2% alkaloids)As it is concentrated, typically synthetically, 7-OH exists at significantly higher levels
Opioid receptor strengthMitragynine, the primary alkaloid in kratom, binds weakly to mu-opioid receptors7-OH binds strongly to mu-opioid receptors, with FDA analysis finding it more potent than morphine
Effect on breathingIncreased breathing rate in rat studiesSlowed breathing, similar to morphine, in rat studies
Naloxone responseNo impact on mitragynine’s effect on breathing in ratsNaloxone fully reversed respiratory depression in rats
Dependence riskLowerHigher, similar to classical opioids, such as morphine, oxycodone, and fentanyl
Common formsPowders, capsules, crushed leaves, resin extracts.Chewable tablets, gummies, drinks mixes


The FDA also warns against kratom use, citing risks such as liver toxicity, seizures, and substance use disorder.

The DEA is planning stricter controls on concentrated 7-OH, with products above a set threshold to be temporarily placed in Schedule I. The order can be published on or after November 13, 2026, and will take effect on the day it is published.

Short-term effects of 7-OH

As 7-OH acts on the same receptors as other opioids, its short-term effects are similar:

  • Pain relief
  • Euphoria
  • Sedation
  • Pinpoint pupils
  • Constipation
  • Itching
  • Respiratory depression

Other adverse effects and health risks

There are several additional adverse effects and health risks associated with 7-OH products:

  • Anxiety and depression
  • Insomnia
  • Seizures
  • Gastrointestinal distress, such as nausea and vomiting
  • Liver injury, reported rarely
  • Addiction and dependence with opioid-like withdrawal symptoms, such as restlessness, body aches, sweating, and irritability
  • Overdose, which can lead to stopped breathing, coma, and death, especially at high doses or when mixed with alcohol or sedatives

The risks are hard to judge because 7-OH products are unregulated and vary widely in potency. Labels may not accurately show how much 7-OH a product contains, and some products may be mixed with other substances.

7-OH addiction risk

Using 7-OH regularly can lead to three related issues: tolerance, physical dependence, and addiction.

First, tolerance goes up as the brain adapts to repeated stimulation of its opioid receptor, resulting in each dose having less of an effect than the next, and users compensating by having more to achieve the desired effect.

Then comes physical dependence, as the body becomes reliant on the drug to function normally. Stopping or reducing dosage triggers withdrawal symptoms, similar to those of morphine and oxycodone.

Addiction is different; it is a pattern of compulsive use despite harm. Chronic use of semi-synthetic drugs, such as 7-OH, can cause opioid-like dependence and addiction. As the effects fade more quickly, people increase their dose frequency, resulting in an addiction-yielding cycle.

Signs of 7-OH addiction

Problems with 7-OH can develop with prolonged use. Signs and symptoms of 7-OH misuse and dependence can be broken up into behavioral and physical indicators.

Behavioural signs

  • Using more, or for longer, than intended
  • Repeated failed attempts to cut back
  • Strong cravings and preoccupation with the next dose
  • Secrecy about use, or money problems from buying it
  • Continuing despite harm to health, work, or relationships

Physical signs

  • Tolerance, which is needing higher doses for the same effect
  • Drowsiness or sedation after use
  • Withdrawal when stopping or cutting back

Exhibiting one of these symptoms doesn’t necessarily amount to an addiction, but if you experience several, it’s worth consulting a healthcare provider.

7-OH withdrawal symptoms

Taking 7-OH regularly can lead to physical dependence, and users who stop suddenly or even gradually can experience withdrawal symptoms characteristic of coming off opioids. These may include:

  • Anxiety and restlessness
  • Strong cravings
  • Insomnia
  • Muscle aches
  • Sweating and chills
  • Runny nose and yawning
  • Nausea, vomiting, or stomach cramps
  • Irritability and low mood

Withdrawal timeline

There is little research to indicate an official timeline for 7-OH withdrawal yet, but it’s likely to follow a pattern similar to withdrawal from other short-acting opioids:

PhaseTimingWhat to expect
Onset8-24 hours after the last doseAnxiety, restlessness, sweating, runny nose, excessive yawning, trouble sleeping
Acute phase4-10 daysMuscle aches, nausea, vomiting, chills, diarrhea, stomach cramps
Protracted withdrawal phaseUp to 6 months thereafterGeneral malaise, strong cravings


It's important to note that a person’s experience with withdrawal may vary depending on several factors, including dose, genetic profile, product strength, and time using 7-OH.

Overdose risk

Taking very high doses of 7-OH can lead to coma, apnea, and death. This risk is increased further when 7-OH is taken with alcohol, benzodiazepines, or other opioids. It is easy to take more than intended due to the different quantities of 7-OH in products across the market.

Signs of an overdose include these:

  • Slowed, shallow breathing
  • Pinpoint pupils
  • Loud snoring, gurgling or choking
  • Limp body
  • Pale, blue-tinged skin
  • Unresponsiveness
  • Unconsciousness

If you suspect an overdose, do not hesitate to call emergency services and stay with them until help arrives. Administer naloxone if it’s available and on hand. Try to keep the person awake and regulate their breathing. It is advisable to lay them on their side to prevent choking.

Treatment for 7-OH addiction

If you or someone you know is struggling with 7-OH addiction, professional intervention is a worthwhile avenue to explore, with several options available.

Medical detox

Stopping 7-OH suddenly can feel very uncomfortable, and attempting to manage withdrawal symptoms alone often leads to relapse. In a medically supervised detox, trained professionals can monitor you and manage your symptoms effectively. You undergo a comprehensive medical assessment, receive nausea medication, and live in a controlled environment designed to optimize your recovery.

While an advisable first step, it’s important to remember that medical detox is the first step of your ongoing treatment, rather than a standalone solution.

Medication-assisted treatment

Buprenorphine, often marketed as suboxone, and methadone are the frontline treatments for 7-OH. As they act on the same receptors as 7-OH, they can ease withdrawal symptoms and cravings without producing the same high.

Timing matters when implementing treatment with either buprenorphine or methadone, so it should be taken in direct accordance with an addiction specialist’s direction.

Inpatient vs outpatient rehab

Inpatient, or residential, rehab is best suited to people with heavy or long-term use, little support at home, histories of past relapses, co-morbid mental health conditions, or other substance use conditions. On-site treatment means you are supervised around the clock and can keep your environment trigger-free.

Outpatient rehab may suit patients with milder dependence, stable home lives and support systems, who are able to function effectively at work or at home. Often, people start as inpatients and then move to outpatient care.

Despite growing concern over its harmful effects, as of mid November 2026, 7-OH is not yet a federally controlled substance in the USA. However, that is set to change imminently.

In July 2026, the DEA announced plans to temporarily place substances that contain 7-OH above a certain threshold in Schedule I, its most restrictive category. In October 2026, it withdrew that notice and published a revised one covering 7-OH and a related compound, mitragynine pseudoindoxyl (MP), above an updated threshold.

Three related compounds, MP, MGM-15, and MGM-16, have been placed in Schedule I since the DEA’s initial announcement.

Once the 7-OH order takes effect, making, selling, or possessing these products will become a criminal offense. The order lasts up to two years, while the DEA works towards a permanent scheduling. The order can be published on or after November 13, 2026, and takes effect on the day it is published. It will last up to two years, with a possible one-year extension, while the DEA works toward permanent scheduling.

Final thoughts

7-OH is often marketed as a harmless alternative to opioids; however, it carries many of the same risks, ranging from dependence to overdose. If you or someone you care about is struggling with 7-OH, there are many treatment options available. Speak to your healthcare provider to access the right medical support today, whether that's medical detox, rehab, or outpatient treatment.

FAQs

Common Questions About 7-OH: Effects, Risks, Withdrawal & Treatment

How long does 7-OH last?

Research on 7-OH in humans is limited, and there is currently no official medical record of the half-life of concentrated 7-OH in humans. That said, the duration of 7-OH effects will, like other substances, depend on several factors, including the amount taken, the method of administration, the user's tolerance, and the user's genetic makeup.

Does 7-OH show up on a drug test?

Not usually, as standard drug tests, including workplace and opiate panels, do not currently screen for 7-OH. There are laboratories that offer specialized tests to detect kratom alkaloids in urine.

Is 7-OH stronger than morphine?

There are studies that show that 7-OH can be up to 13 times more potent than morphine at the brain’s opioid receptors. However, no human clinical trials have verified that 7-OH affects humans in the same way. Nonetheless, its perceived strength and unregulated product marketing contribute to the DEA's push to schedule 7-OH.

Was this page helpful?

Your feedback allows us to continually improve our information

Resources:

  1. Lydecker, A. G., Sharma, A., McCurdy, C. R., Avery, B. A., Babu, K. M., & Boyer, E. W. (2016). Suspected adulteration of commercial kratom products with 7-hydroxymitragynine. Journal of Medical Toxicology, 12(4), 341–349.
  2. Kruegel, A. C., Uprety, R., Grinnell, S. G., Langreck, C., Pekarskaya, E. A., Le Rouzic, V., Ansonoff, M., Gassaway, M. M., Pintar, J. E., Pasternak, G. W., Javitch, J. A., Majumdar, S., & Sames, D. (2019). 7-Hydroxymitragynine is an active metabolite of mitragynine and a key mediator of its analgesic effects. ACS Central Science, 5(6), 992–1001. PubMed Central.
  3. "When An Herbal Supplement Becomes A Potent Opioid: The Emerging Threat Of Concentrated Kratom Derivatives," Health Affairs Forefront, May 14, 2026.
  4. FDA. (2025). 7-Hydroxymitragynine (7-OH): An assessment of the scientific data and toxicological concerns around an emerging opioid threat [Scientific assessment].
  5. Zuarth Gonzalez, J. D, Ragsdale, A. K., Mukhopadhyay, S., McCurdy, C. R., McMahon, L. R., Obeng, S., & Wilkerson, J. L. (2025). Mitragynine and 7-Hydroxymitragynine: Bidirectional effects on breathing in rats. bioRxiv : The Preprint Server for Biology, 2025.05.16.654392. PubMed Central. .
  6. ToxTalks: A bulletin for healthcare professionals who manage poisoned patients. (n.d.). Retrieved November 2, 2026, from
  7. U.S. Food and Drug Administration. (2019). FDA and Kratom. U.S. Food and Drug Administration.
  8. Schedules of controlled substances: Temporary placement of 7- hydroxymitragynine and mitragynine pseudoindoxyl above a specified threshold in schedule I. (2026, October 14). Federal Register.
  9. Blue Ridge Poison Center at UVA Health. (2025). 7-Hydroxymitragynine: The newest smoke shop craze (pp. 1–3) [Healthcare bulletin on emerging toxicants].
  10. Kansas Department of Health and Environment, & U.S. Food and Drug Administration. (2025, September 25). KDHE warns about effects of 7-hydroxymitragynine (7-OH) drug usage. Salina Post.
  11. Smith, K. E., Boyer, E. W., Grundmann, O., McCurdy, C. R., & Sharma, A. (2024). The rise of novel, semi‐synthetic 7‐hydroxymitragynine products. Addiction, 120(2), 387–388.
  12. World Health Organization. (2009). Withdrawal management. ; World Health Organization.
  13. Centers for Disease Control and Prevention. (n.d.). Know the signs of an opioid overdose [Postcard]. Rx Awareness Campaign.
  14. Wightman, R. S., & Hu, D. (2025). A case of 7-Hydroxymitragynine use requiring inpatient medically managed withdrawal. Journal of Addiction Medicine, 20(4), 416–418.
  15. Sherrick, R. C. (2026). Treatment of kratom use disorder with methadone in an opioid treatment program. Journal of Addiction Medicine, 20(6), e239–e241. PubMed.
  16. National Institute on Drug Abuse. (2014, June 13). Treatment. National Institute on Drug Abuse.
  17. Temporary control of 7-Hydroxymitragynine (7-OH) and related substances under the controlled substances act. (2026). .
  18. Huestis, M. A., Brett, M. A., Bothmer, J., & Atallah, R. (2024). Human mitragynine and 7-Hydroxymitragynine pharmacokinetics after single and multiple daily doses of oral encapsulated dried kratom leaf powder. Molecules, 29(5), 984.

Activity History - Last updated: 17 November 2026, Published date:


Reviewer

Dr. Jennie Stanford

MD, FAAFP, DipABOM

Jennie Stanford, MD, FAAFP, DipABOM is a dual board-certified physician in both family medicine and obesity medicine. She has a wide range of clinical experiences, ranging from years of traditional clinic practice to hospitalist care to performing peer quality review to ensure optimal patient care.

Activity History - Medically Reviewed on 13 November 2026 and last checked on 17 November 2026

Medically reviewed by
Dr. Jennie Stanford

Dr. Jennie Stanford

MD, FAAFP, DipABOM

Reviewer

Recovered Branding BG
Ready to talk about treatment? Call today. (833) 840-1202
Helpline Information

Calls to numbers marked with (I) symbols will be answered or returned by one of the treatment providers listed in our Terms and Conditions, each of which is a paid advertiser.

In calling the helpline you agree to our Terms and Conditions. We do not receive any fee or commission dependent upon which treatment or provider a caller chooses.

There is no obligation to enter treatment.

Access State-Specific Provider Directories for detailed information on locating licensed service providers and recovery residences in your area.

For any specific questions please email us at info@recovered.org

Related guides